← SynDRA
ANDROGRAPHOLIDE
SynDRA canonical compound SYN0005654 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | IL1B | IL6 | NFKB1 | NFKB2 | TNF |
|---|
| Mechanism of action | tumor necrosis factor production inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- tumor necrosis factor production inhibitor
Drug classes
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antiprotozoal Agents
- Antiviral Agents
- Platelet Aggregation Inhibitors
Cross-references
Synonyms
- HMPL-004
- HMPL004
- NSC-383468
- Andrographis
- UNII-410105JHGR
- CHEBI:65408
- 410105JHGR
- (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one
- AK-47364
- 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one
- EINECS 226-852-5
- NSC 383468
- 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone
- Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
- TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
- IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
- IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
- DTXCID1025980
- RefChem:5554
- MFCD07778082
- NSC383468
- NCGC00095597-01
- Andrographolide CRS
- Andrographiside aglycon
- Andrographolide, 98%
- Andrographolide (Standard)
- Andrographolide Impurity 3
- ANDROGRAPHOLIDE [MI]
- BIDD:ER0530
- GTPL9675
- MEGxp0_000978
- orb1304874
- orb3139603
- ANDROGRAPHOLIDE [USP-RS]
- ANDROGRAPHOLIDE [WHO-DD]
- SCHEMBL12056309
- ACon1_002113
- HY-N0191R
- Andrographolide, analytical standard
Look up ANDROGRAPHOLIDE in the interactive SynDRA portal →